Rafferty Asset Management, LLC Rocket Pharmaceuticals, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 128,726 shares of RCKT stock, worth $1.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

128,726

Previous 117,645 9.42%

Holding current value

$1.45 Million

Previous $2.53 Million 6.12%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$17.6 - $25.88 $195,025 - $286,776	11,081 Added 9.42%	128,726 $2.38 Million
Q2 2024 Aug 13, 2024	SELL	$20.66 - $26.72 $4.37 Million - $5.65 Million	-211,398 Reduced 64.25%	117,645 $2.53 Million
Q1 2024 May 13, 2024	BUY	$26.16 - $30.74 $3.15 Million - $3.71 Million	120,538 Added 57.81%	329,043 $8.86 Million
Q4 2023 Feb 13, 2024	SELL	$16.78 - $31.94 $556,038 - $1.06 Million	-33,137 Reduced 13.71%	208,505 $6.25 Million
Q3 2023 Nov 13, 2023	BUY	$15.07 - $24.05 $128,969 - $205,819	8,558 Added 3.67%	241,642 $4.95 Million
Q2 2023 Aug 11, 2023	SELL	$16.59 - $23.6 $1.1 Million - $1.57 Million	-66,375 Reduced 22.16%	233,084 $4.63 Million
Q1 2023 May 11, 2023	BUY	$15.79 - $22.6 $86,813 - $124,254	5,498 Added 1.87%	299,459 $5.13 Million
Q4 2022 Feb 13, 2023	BUY	$15.5 - $22.76 $1.05 Million - $1.54 Million	67,443 Added 29.77%	293,961 $5.75 Million
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $1.73 Million - $2.58 Million	139,896 Added 161.5%	226,518 $3.62 Million
Q2 2022 Aug 12, 2022	SELL	$7.96 - $16.64 $626,061 - $1.31 Million	-78,651 Reduced 47.59%	86,622 $1.19 Million
Q1 2022 May 13, 2022	BUY	$13.16 - $23.68 $274,596 - $494,106	20,866 Added 14.45%	165,273 $2.62 Million
Q4 2021 Feb 10, 2022	BUY	$21.52 - $36.02 $1.21 Million - $2.02 Million	56,213 Added 63.74%	144,407 $3.15 Million
Q3 2021 Nov 10, 2021	BUY	$27.42 - $48.97 $869,405 - $1.55 Million	31,707 Added 56.13%	88,194 $2.64 Million
Q2 2021 Aug 10, 2021	SELL	$39.41 - $47.25 $222,508 - $266,773	-5,646 Reduced 9.09%	56,487 $2.5 Million
Q1 2021 May 10, 2021	BUY	$43.34 - $65.91 $2.39 Million - $3.64 Million	55,163 Added 791.43%	62,133 $2.76 Million
Q4 2020 Feb 10, 2021	SELL	$23.3 - $59.57 $695,551 - $1.78 Million	-29,852 Reduced 81.07%	6,970 $382,000
Q3 2020 Nov 13, 2020	BUY	$20.5 - $28.59 $450,487 - $628,265	21,975 Added 148.01%	36,822 $842,000
Q2 2020 Aug 07, 2020	BUY	$13.32 - $22.61 $197,762 - $335,690	14,847 New	14,847 $311,000
Q1 2020 May 15, 2020	SELL	$9.71 - $25.11 $153,252 - $396,311	-15,783 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$11.07 - $24.23 $278,941 - $610,547	-25,198 Reduced 61.49%	15,783 $359,000
Q3 2019 Nov 14, 2019	SELL	$10.85 - $14.78 $40,513 - $55,188	-3,734 Reduced 8.35%	40,981 $477,000
Q2 2019 Aug 09, 2019	BUY	$15.0 - $19.81 $206,880 - $273,219	13,792 Added 44.6%	44,715 $671,000
Q1 2019 May 15, 2019	BUY	$13.45 - $19.01 $415,914 - $587,846	30,923 New	30,923 $542,000

Others Institutions Holding RCKT

# of Institutions

213

Shares Held

93.1M

Call Options Held

319K

Put Options Held

70.3K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $851M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Rocket Pharmaceuticals, Inc. Transaction History